Trial Profile
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Early breast cancer
- Focus Biomarker; Therapeutic Use
- 13 Jun 2012 Official Title amended as reported by ClinicalTrials.gov.
- 13 Jun 2012 Actual patient number changed from 16 to 27 according to ClinicalTrials.gov.
- 29 Dec 2011 Actual patient number is 16 according to ClinicalTrials.gov.